• NAV reached €35.5 billion at 31 December 2023 with NAV per share increasing by 32.7%, outperforming the MSCI World Index by 15.1 p.p.

Clarivate and Exor Sign Agreement Under Which Suzanne Heywood Will Be Nominated to Stand for Election to the Company’s Board of Directors

Exor becomes a long-term investor in Clarivate, endorsing the strategic direction set out by the Company’s Management and Board, and announces it now has a 10.1% shareholding in the Company and can increase its participation up to 17.5%

Exor N.V. announces the settlement of the previously announced offering of Euro 650 million notes priced on 7 February 2024 with a fixed annual coupon of 3.750% and due on 14 February 2033.

The notes have been listed on the Luxembourg Stock Exchange, admitted for trading on the Euro MTF Market and assigned a credit rating of A- by Standard and Poor’s rating agency.

Exor N.V. (rated A- with stable outlook by Standard & Poor’s) announces the pricing of Euro 650 million notes due on 14 February 2033, with an issue price of 99.371% and a fixed annual coupon of 3.75%.

The purpose of the issue is to raise new funds for Exor’s general corporate purposes and refinance debt maturing in 2024.

The notes will be listed on the Luxembourg Stock Exchange, admitted for trading on the Euro MTF Market, and the settlement of the issue will take place on 14 February 2024.

EXOR N.V. announced today the following Corporate Calendar for 2024:

• 10 April 2024: Board of Directors Meeting for the approval of the Company’s 2023 Annual Report

• 28 May 2024: Annual General Meeting of Shareholders for the adoption of the Company’s 2023 Financial Statements

• 25 September 2024: Board of Directors Meeting for the approval of the Company’s 2024 Half-Year Financial Report